Edition:
United States

Lonza Group AG (LZAGF.PK)

LZAGF.PK on OTC Markets Group

206.67USD
--
Change (% chg)

-- (--)
Prev Close
$206.67
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
210
52-wk High
$210.77
52-wk Low
$157.68

Select another date:

Tue, Apr 25 2017

BRIEF-Lonza aims to raise 2.25 billion Sfr with new rights offering

* Says determined the final terms of the capital increase by way of a rights offering

Lonza to seek shareholder sign-off on 2.3 billion Sfr rights issue

ZURICH Lonza Group AG will ask shareholders at next month's annual general meeting for permission to issue up to 2.3 billion Swiss francs ($2.3 billion) in new shares to finance its acquisition of U.S. capsule maker Capsugel, the Swiss pharmaceutical supplier said on Thursday.

Lonza to seek shareholder sign-off on 2.3 bln Sfr rights issue

ZURICH, March 30 Lonza Group AG will ask shareholders at next month's annual general meeting for permission to issue up to 2.3 billion Swiss francs ($2.3 billion) in new shares to finance its acquisition of U.S. capsule maker Capsugel, the Swiss pharmaceutical supplier said on Thursday.

BRIEF-Lonza and Selecta Biosciences announces manufacturing agreement for Anc80-AAV-based gene therapy

* Lonza and Selecta Biosciences announce manufacturing agreement for Anc80-AAV-based gene therapy for treatment of methylmalonic acidemia

BRIEF-Bookrunner says transaction covered in Lonza Group placing

* Lonza Group AG: bookrunner says transaction covered in accelerated bookbuild Further company coverage: (Bengaluru Newsroom)

BRIEF-Bookrunner gives pricing guidance on Lonza Group offering

* Lonza Group AG ABB: bookrunner says visibility on potential investor interest in excess of 70 pct the deal size, from a limited market sounding exercise

BRIEF-Lonza launches accelerated bookbuilding

* Following the announcement on 15 December 2016 regarding the contemplated acquisition of Capsugel, Lonza launches an accelerated bookbuilding by offering up to 5.0 million registered shares

Lonza to buy U.S. drug capsule maker Capsugel from KKR for $5.5 billion

Swiss pharmaceutical supplier Lonza Group AG on Thursday announced a deal to buy Capsugel, a U.S. maker of capsules and other drug delivery systems, from KKR & Co LP for $5.5 billion in cash to broaden its product range.

Exclusive: Lonza says in talks to buy Capsugel; deal could top $5 billion - sources

Swiss pharmaceutical manufacturer Lonza Group AG on Monday confirmed it is in advanced talks with private equity firm KKR & Co LP to acquire Capsugel, a U.S. maker of capsule products and other drug delivery systems.

Select another date:

More From Around the Web